 | • レポートコード：B-MOR-08136 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、避妊具の世界市場について調べ、避妊具の世界規模、市場動向、市場環境、タイプ別（コンドーム、ペッサリー、子宮頸管キャップ 、スポンジ、膣リング、子宮内に瀕具、埋め込み型避妊具）分析、性別（男性、女性）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・避妊具の世界市場インサイト ・避妊具の世界市場環境 ・避妊具の世界市場動向 ・避妊具の世界市場規模 ・避妊具の世界市場規模：タイプ別（コンドーム、ペッサリー、子宮頸管キャップ 、スポンジ、膣リング、子宮内に瀕具、埋め込み型避妊具） ・避妊具の世界市場規模：性別（男性、女性） ・避妊具の世界市場：地域別市場規模・分析 ・避妊具の北米市場規模・予測 ・避妊具のアメリカ市場規模・予測 ・避妊具のヨーロッパ市場規模・予測 ・避妊具のアジア市場規模・予測 ・避妊具の日本市場規模・予測 ・避妊具の中国市場規模・予測 ・避妊具のインド市場規模・予測 ・避妊具の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global contraceptive devices market was valued at around USD 20 billion in 2017 and is projected to register a CAGR of approximately 7% during the forecast period 2018–2023. China, the world’s most populated country, with a population of around 1.36 billion, has one of the highest rates of contraceptives usage.
Government Initiatives to Prevent Unwanted Abortions and Pregnancies
Unwanted pregnancies are on the rise, globally. Government bodies of various countries have been taking measures, like promoting the use of contraceptive devices to prevent this unwanted growth. It is estimated that among the number of pregnancies that occur in the United States, nearly 76% of them are unwanted, and are under the age of 30. According to Harvard researchers, it is estimated that single parenthood due to unwanted pregnancies is the reason for holding out on economic mobility, more than other variables like education and race. Given the widespread implications of unwanted pregnancies, the market for contraceptive devices is expected to experience a surge during the forecast period. Also, other factors, like the increasing incidence of STDs and the rapid increase in population, will accelerate the growth of the contraceptive devices market.
Limited Access to Contraception
Access to safe, voluntary family planning is a human right. Family planning is central to gender equality and women’s empowerment and is a key factor in reducing poverty. Millions of women are unable to prevent unwanted pregnancies, which is impacting their lifestyle, as well as that of the child, both economically and socially. This is happening primarily due to the lack of knowledge and limited access to contraception and is more prevalent among low and middle-income nations of the world. An estimated 69 countries face the problem of limited access to contraception. Lack of awareness and limited supply has been one of the major reasons for the contraceptive devices market’s limited growth in the developing nations. Apart from these, the high cost of conventional contraceptive devices, like intra-uterine device (IUD), is also acting as a barrier to the growth of the market.
United States Holds the Largest Market Share
There were approximately 60 million women in the United States in their child-bearing years (age 15 – 44), as of 2017. Around 70% of these women were at risk of unintended pregnancy. More than 99% of women aged between 15 – 44 years have used at least one contraceptive method. This indicates the high awareness and demand for avoiding unintended pregnancies in the United States. The use of contraceptive devices accounts for the second largest expenditure on contraceptive methods in the United States, and globally alike.
Key Developments in the Market
• November 2017: Teva Pharmaceuticals has signed an agreement with CooperSurgical to acquire PARAGARD® (an intrauterine copper contraceptive product).
• July 2017: Teva Pharmaceutical has announced the launch of Vagifem®1 (estradiol vaginal inserts), 10 mcg in the United States.
Major Players: BAYER HEALTHCARE, PFIZER, MERCK & CO., CHURCH & DWIGHT CO., INC., TEVA PHARMACEUTICALS, AGILE THERAPEUTICS, INC., ACTAVIS PLC, FUJI LATEX CO. LTD, PANTARHEI BIOSCIENCE B.V., LUPIN PHARMACEUTICALS, BIOSANTE PHARMACEUTICALS, AND THE FEMALE HEALTH COMPANY, among others.
Reasons to Purchase the Report
• To understand the current and future contraceptive devices market in the developed and emerging markets.
• Analyzing various perspectives of the market with the help of Porter’s Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3 month analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Product Innovation
6.1.2 Increasing Incidence of STDs
6.1.3 Rise in Government Initiatives to Prevent Unwanted Abortions and Pregnancies
6.2 Restraints
6.2.1 Cultural or Religious Opposition
6.2.2 Limited Access to Contraception
6.2.3 Infertility Issues
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type
7.1.1 Condoms
7.1.2 Diaphragms
7.1.3 Cervical Caps
7.1.4 Sponges
7.1.5 Vaginal Rings
7.1.6 Intra Uterine Devices
7.1.7 Implants
7.2 By Gender
7.2.1 Male
7.2.2 Female
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.1.4 Rest of North America
7.3.2 Europe
7.3.2.1 United Kingdom
7.3.2.2 Germany
7.3.2.3 France
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 Gcc
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Actavis PLC
9.2 Agile Therapeutics
9.3 Bayer Healthcare
9.4 Fuji Latex Co. Ltd
9.5 Johnson & Johnson
9.6 Lupin Pharmaceuticals
9.7 Merck & Co.
9.8 Pfizer
9.9 Reckitt Benckiser Group PLC
9.10 Teva Pharmaceuticals
9.11 The Female Health Company
9.12 Others
10. Future of the Market